Skip to main content

Generalized Lipodystrophy

1
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Amryt Pharma
Amryt PharmaUK - London
1 program
1
metreleptinPhase 43 trials
Active Trials
NCT06502990Terminated1Est. Feb 2026
NCT06484868Recruiting12Est. Feb 2028
NCT05351164Active Not Recruiting4Est. Oct 2028

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
Amryt Pharmametreleptin
Amryt Pharmametreleptin
Amryt Pharmametreleptin

Clinical Trials (3)

Total enrollment: 17 patients across 3 trials

NCT06484868Amryt Pharmametreleptin

Open-label Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy

Start: Feb 2024Est. completion: Feb 202812 patients
Phase 4Recruiting
NCT06502990Amryt Pharmametreleptin

Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy

Start: May 2025Est. completion: Feb 20261 patients
Phase 3Terminated
NCT05351164Amryt Pharmametreleptin

Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Start: Aug 2023Est. completion: Oct 20284 patients
Phase 2Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 17 patients
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.